Group 1 - The Dow futures rose by 0.08%, while S&P 500 futures fell by 0.13% and Nasdaq futures decreased by 0.28% [1] - Critical Metals surged over 10%, MP Materials increased by over 3%, and USA Rare Earth rose by over 2% in pre-market trading, indicating strength in the rare earth sector [1] - Bitcoin dropped below $92,000, currently at $91,988.3, reflecting a 1.63% decline in the past 24 hours, while Ethereum fell to $3,225.79, down 0.04% [1] - Baidu's stock increased by nearly 1.5% after receiving the first fully autonomous driving test license in Dubai and plans to launch a local operations center [1] - Ventyx, a biopharmaceutical company, soared by 65% in pre-market trading as reports emerged that Eli Lilly is close to finalizing a deal to acquire the company for over $1 billion [1] - Truist Securities initiated coverage on Palantir, giving it a "buy" rating with a target price of $223, citing significant opportunities in driving government and enterprise adoption of general artificial intelligence despite its high valuation [1] Group 2 - Vodafone's stock rose nearly 3% following a preliminary agreement with Fastweb to collaborate on mobile access network development through a shared wireless access network model [2] - Berkshire Hathaway announced a salary increase for new CEO Greg Abel to $25 million, which is 250 times the fixed annual salary of his predecessor Warren Buffett, who earned $100,000 for over 40 years [2] - Citigroup predicts that copper prices may peak in January, expecting prices to rise to $14,000 per ton in the next three months due to strong momentum, but warns that prices could peak this month without new catalysts [2]

美国生物制药公司Ventyx Biosciences(VTYX.US)盘前飙升70%，报17.11美元。据华尔街日报引述消息 称，礼来就拟以超过10亿美元收购Ventyx Biosciences的交易进行深入谈判。潜在收购Ventyx将为礼来的 产品管线增加治疗炎症性肠病的药物，以及治疗帕金森等疾病的药物。此外，Ventyx的一种实验性药物 目前正在中期开发阶段，用于治疗与肥胖相关的心血管疾病。(格隆汇) ...

Core Viewpoint - The article highlights five top stocks to consider for investment in early 2026, emphasizing their strong earnings potential and growth opportunities in various sectors. Group 1: Amazon - Amazon is positioned as a strong investment due to its leadership in e-commerce and cloud computing, with a market cap of $2.6 trillion and a gross margin of 50.05% [5][3] - The company is leveraging artificial intelligence to enhance its e-commerce efficiency and AWS has an annual revenue run rate exceeding $132 billion [5][3] - The stock is considered a safe bet with a current price of $240.95, reflecting a 3.38% increase [4][3] Group 2: Eli Lilly - Eli Lilly is a leader in the weight loss drug market, particularly with its products tirzepatide (Zepbound and Mounjaro), contributing to significant sales growth [6][8] - The company has a market cap of $1 trillion and a gross margin of 83.03%, with a current stock price of $1,064.04, up 2.16% [7][6] - The weight loss drug market is projected to reach nearly $100 billion by the end of the decade, indicating substantial growth potential for Lilly [9] Group 3: Chewy - Chewy operates in the pet e-commerce space, expanding into veterinary services, which broadens its revenue opportunities [10][12] - The company has achieved profitability and 84% of its sales come from its Autoship service, providing predictable revenue [12][11] - Chewy's current market cap is $13 billion, with a gross margin of 28.58% and a stock price of $32.16, reflecting a slight increase of 0.05% [11][10] Group 4: Apple - Apple has underperformed compared to the S&P 500 but is now focusing on AI features, which may attract investors looking for growth [14][15] - The company has a market cap of $3.9 trillion and a gross margin of 46.91%, with a current stock price of $262.36, down 1.83% [15][14] - Apple's services segment is a significant growth area, consistently reporting record revenues [16] Group 5: Moderna - Moderna is identified as a recovery story, facing challenges due to declining vaccine sales but has a promising pipeline of late-stage candidates [18][19] - The company aims to expand its seasonal vaccine offerings from three to six products by 2028 and is working towards cash breakeven [19][20] - Moderna has a market cap of $14 billion, a gross margin of 38.93%, and a current stock price of $35.66, reflecting a 10.85% increase [19][18]

智通财经APP获悉，据报道，礼来(LLY.US)正就以超过10亿美元的价格收购Ventyx Biosciences(VTYX.US)进行深入谈判，以拓展其在免疫学领域的业务。截至发稿，Ventyx股价在美股夜 盘交易中上涨62.59%，至16.34美元。这家总部位于圣地亚哥的生物技术公司专注于研发治疗克罗恩病 和类风湿性关节炎等炎症性疾病的药物，按此价格计算，其市值将增加4.339亿美元。Ventyx收购案的 报道正值制药行业准备参加在旧金山举行的摩根大通医疗保健大会之际，该大会历来是并购交易的热门 场所。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者 ...

与此同时，该公司正在寻求收购以扩充其产品线。2024年，该公司以32亿美元收购了Morphic Therapeutics，获得了一种用于治疗炎症性肠病的实验性药物。此外，该公司还斥资24亿美元收购了 Dice Therapeutics，后者是一家开发口服银屑病疗法的公司。 礼来公司表示，免疫学是其关键增长领域，该公司希望在糖尿病和肥胖症治疗领域取得巨大成功的基础 上，进一步拓展业务。这些成功吸引了投资者和患者的关注。该公司目前已销售多种治疗关节炎和银屑 病等炎症性疾病的药物，包括Taltz，但Taltz的关键专利保护将在未来几年内到期。 据报道，礼来(LLY.US)正就以超过10亿美元的价格收购Ventyx Biosciences(VTYX.US)进行深入谈判，以 拓展其在免疫学领域的业务。截至发稿，Ventyx股价在美股夜盘交易中上涨62.59%，至16.34美元。这 家总部位于圣地亚哥的生物技术公司专注于研发治疗克罗恩病和类风湿性关节炎等炎症性疾病的药物， 按此价格计算，其市值将增加4.339亿美元。Ventyx收购案的报道正值制药行业准备参加在旧金山举行 的摩根大通医疗保健大会之际，该大会历来是并购交易 ...

对文泰克斯公司的潜在收购将使礼来获得治疗炎症性肠病（如克罗恩病和溃疡性结肠炎）的药物，同时 还将获得治疗帕金森症等疾病的药物。 文泰克斯公司的一种实验性药物目前正处于治疗与肥胖相关的心血管疾病这一阶段的研发过程中。 据知情人士透露，礼来公司正在就收购文泰克斯生物科学公司（Ventyx Biosciences）进行深入谈判，交 易金额可能超过 10 亿美元。 受此消息推动，文泰克斯公司的股价在盘后交易中上涨了超过 50%。 责任编辑：于健 SF069 据知情人士透露，礼来公司正在就收购文泰克斯生物科学公司（Ventyx Biosciences）进行深入谈判，交 易金额可能超过 10 亿美元。 受此消息推动，文泰克斯公司的股价在盘后交易中上涨了超过 50%。 对文泰克斯公司的潜在收购将使礼来获得治疗炎症性肠病（如克罗恩病和溃疡性结肠炎）的药物，同时 还将获得治疗帕金森症等疾病的药物。 文泰克斯公司的一种实验性药物目前正处于治疗与肥胖相关的心血管疾病这一阶段的研发过程中。 责任编辑：于健 SF069 ...

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC. ©2026 Investor's Business Daily, LLC. All Rights Reserved. Terms of Use Privacy Notice Accessibility About Us Reviews Site Map Your Ad Choices Advertising Contact us IBD Stock Charts IBD Stock Checkup Stock Quotes Stock Market Today The Big Picture My Stock Lists IBD Live Leaderboard SwingTrader MarketSurge IBD Digital MarketDiem The ...

Core Viewpoint - The article aims to provide informational content regarding investment opportunities and risks, emphasizing the importance of independent research and verification by readers [2][3]. Group 1: Company Analysis - The article does not provide specific details about any particular company or its financial performance, focusing instead on general investment advice [2][3]. Group 2: Industry Insights - There are no specific insights or analyses related to any industry mentioned in the article, as it primarily serves as a general informational piece [2][3].

Eli Lilly is in advanced talks to buy Ventyx Biosciences for over $1 billion, the Wall Street Journal reported on Tuesday, citing people familiar with the matter. ...

Group 1 - The deal is valued at more than $1 billion and is expected to be finalized imminently [1]